Foghorn Therapeutics (FHTX) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Foghorn Therapeutics (FHTX) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 52.7% versus a loss of 67.2%. Over five years, FHTX leads with a -83.1% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($129.5 million vs $124.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | TNXP |
|---|---|---|
| Share price | $2.09 | $7.55 |
| Market cap | $124.12M | $129.49M |
| 1-day change | +6.09% | -1.88% |
| YTD return | -61.30% | -51.66% |
| 1-year return | -52.71% | -67.17% |
| 5-year return | -83.12% | -100.00% |
| EPS (TTM) | $-1.04 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $23.25 |
| 52-week low | $1.79 | $7.42 |
| Distance from 52-week high | -72.54% | -67.53% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +187.08% | +489.40% |
| Average volume | 611.95K | 537.24K |
| Shares outstanding | 59.39M | 17.15M |
| Employees | 106 | 142 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FHTX has outperformed TNXP by 14.5 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Healthcare · Biotechnology · 106 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Healthcare · Biotechnology · 142 employees
FHTX vs TNXP FAQ
Which is bigger, Foghorn Therapeutics or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $129.49M compared with $124.12M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or TNXP?
FHTX returned -52.71% over the past 12 months, compared with -67.17% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.